share_log

Cantor Fitzgerald Initiates Coverage On Novo Nordisk With Overweight Rating, Announces Price Target of $120

Cantor Fitzgerald Initiates Coverage On Novo Nordisk With Overweight Rating, Announces Price Target of $120

坎托·菲茨杰拉德以增持评级启动对诺和诺德的报道,宣布目标股价为120美元
Benzinga ·  2023/12/01 08:49

Cantor Fitzgerald analyst Louise Chen initiates coverage on Novo Nordisk (NYSE:NVO) with a Overweight rating and announces Price Target of $120.

坎托·菲茨杰拉德分析师路易丝·陈以增持评级开始对诺和诺德(纽约证券交易所代码:NVO)进行报道,并宣布目标股价为120美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发